Rain Oncology Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Rain Oncology prognostiziert ein Gewinnwachstum at 23.3% per annum. Der Gewinn pro Aktie wird voraussichtlich wachsen um 26.9% pro Jahr.

Wichtige Informationen

23.3%

Wachstumsrate der Gewinne

26.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.9%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	03 Jan 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is Rain Oncology (NASDAQ:RAIN) In A Good Position To Invest In Growth?

Feb 23

We Think Rain Therapeutics (NASDAQ:RAIN) Needs To Drive Business Growth Carefully

Nov 08

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:RAIN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	N/A	-30	N/A	N/A	1
12/31/2025	N/A	-26	N/A	N/A	1
12/31/2024	N/A	-46	N/A	N/A	2
12/31/2023	N/A	-64	N/A	N/A	2
9/30/2023	N/A	-72	-68	-66	N/A
6/30/2023	N/A	-83	-74	-74	N/A
3/31/2023	N/A	-79	-68	-68	N/A
12/31/2022	N/A	-76	-63	-63	N/A
9/30/2022	N/A	-71	-60	-60	N/A
6/30/2022	N/A	-71	-59	-56	N/A
3/31/2022	N/A	-62	-52	-50	N/A
12/31/2021	N/A	-51	-40	-37	N/A
9/30/2021	N/A	-39	-35	-32	N/A
6/30/2021	N/A	-31	-28	-23	N/A
3/31/2021	N/A	-25	-19	-14	N/A
12/31/2020	N/A	-21	-16	-11	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: RAIN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: RAIN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: RAIN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: Die Daten reichen nicht aus, um festzustellen, ob die Einnahmen von RAIN schneller wachsen werden als der Markt von US.

Hohe Wachstumseinnahmen: RAIN wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von RAIN in 3 Jahren voraussichtlich hoch sein wird

Rain Oncology Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 69% to US$1.44

Price target decreased by 30% to US$4.65

Price target decreased by 59% to US$7.46

Price target increased by 7.4% to US$19.44

Price target decreased to US$18.00

Price target decreased to US$16.17

Recent updates

Rain Oncology Files Form 15

Rain Oncology to Delist from Nasdaq

Pathos AI, Inc. entered into a definitive merger agreement to acquire Rain Oncology Inc. (NasdaqGS:RAIN) for $42.2 million.

Pathos AI, Inc. entered into a definitive merger agreement to acquire Rain Oncology Inc. (NasdaqGS:RAIN) for $42.2 million.

New minor risk - Shareholder dilution

Price target decreased by 69% to US$1.44

Price target decreased by 30% to US$4.65

Rain Oncology Inc., Proterra Inc., Bioxcel Therapeutics, Inc Announces Class Action Update

Rain Oncology Inc. to Report Q2, 2023 Results on Aug 10, 2023

Levi & Korsinsky, LLP Files a Complaint to Recover Losses Suffered by Purchasers of Rain Oncology Inc. Securities

Price target decreased by 59% to US$7.46

Rain Oncology Inc. Announces Topline Results from Phase 3 MANTRA Trial of Milademetan for Treatment of Dedifferentiated Liposarcoma

Price target increased by 7.4% to US$19.44

Is Rain Oncology (NASDAQ:RAIN) In A Good Position To Invest In Growth?

Rain Oncology Inc. Announces Phase 1 Clinical Data of Milademetan Publishes in Journal of Clinical Oncology

Senior VP & Head of Research notifies of intention to sell stock

lead Independent Director recently bought US$988k worth of stock

We Think Rain Therapeutics (NASDAQ:RAIN) Needs To Drive Business Growth Carefully

Rain Therapeutics Provides Interim Analysis of Phase 2 Basket Trial of Milademetan for Mdm2-Amplified Advanced Solid Tumors

Rain Therapeutics Inc. to Report Q3, 2022 Results on Nov 10, 2022

Price target decreased to US$18.00

Rain Therapeutics Inc. Announces Completion of Enrollment in Phase 3 MANTRA Trial for Milademetan in Liposarcoma

Rain Therapeutics GAAP EPS of -$0.66 in-line

Here's Why We're Watching Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Situation

Rain Therapeutics Inc.(NasdaqGS:RAIN) dropped from Russell 2500 Value Index

Co-Founder recently bought US$57k worth of stock

Price target decreased to US$16.17

Price target decreased to US$18.00

Rain Therapeutics Inc., Annual General Meeting, Jun 01, 2022

We're Not Very Worried About Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Rate

Co-Founder notifies of intention to sell stock

Rain Therapeutics Inc. Announces the Appointments of Several Industry Veterans to the Leadership Team

We Think Rain Therapeutics (NASDAQ:RAIN) Can Afford To Drive Business Growth

Independent Director recently bought US$54k worth of stock

We're Hopeful That Rain Therapeutics (NASDAQ:RAIN) Will Use Its Cash Wisely

Rain Therapeutics Inc. Presents Non-Clinical Data on Milademetan (RAIN-32) in Malignant Pleural Mesothelioma at the IASLC 2021 World Conference on Lung Cancer

Independent Director recently bought US$2.1m worth of stock

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken